Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

30 citing papers in PubMed, 109 citations in OpenAlex.

1. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase.Leukemia · 2003
   Trial
2. [Philadelphia chromosome-negative myeloid neoplasms in patients with Philadelphia chromosome-positive chronic myeloid leukemia during tyrosine kinase inhibtor-therapy].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2019
   Article
3. The -7 chromosomal abnormalities with signs of myelodysplasia in chronic myeloid leukemia as a major red signal.Haematologica · 2019
   Article
4. Secondary clonal hematologic neoplasia following successful therapy for acute promyelocytic leukemia (APL): A report of two cases and review of the literature.Leukemia research reports · 2018
   Article
5. [Clinical observation of chromosomal abnormalities in Ph negative cells of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2016
   Article
6. Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis.Journal of hematology & oncology · 2015
   Article
7. Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia.Medical oncology (Northwood, London, England) · 2013
   Article
8. Persistence of derivative chromosome 22 after achieving a major molecular response in chronic myeloid leukemia with a cryptic BCR-ABL1 fusion gene.International journal of hematology · 2009
   Article
9. t(5;6;12) associated with resistance to imatinib mesylate in chronic myeloid leukemia.International journal of hematology · 2009
   Article
10. Emergence of abnormal clone with monsomy 7 in Philadelphia negative cells of CML patients treated with tyrosine kinase inhibitors.International journal of hematology · 2009
    Article
11. Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells.Oncogene · 2008
    Article
12. Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform.Wiener klinische Wochenschrift · 2008
    Article
13. Cytogenetic evolution patterns in CML post-SCT.Bone marrow transplantation · 2007
    Article
14. Monitoring BCR-ABL in the treatment of chronic myeloid leukemia by polymerase chain reaction.Current hematologic malignancy reports · 2006
    Review
15. Induction of centrosome and chromosome aberrations by imatinib in vitro.Leukemia · 2005
    Article
16. Gene expression profiling of Philadelphia chromosome (Ph)-negative CD34+ hematopoietic stem and progenitor cells of patients with Ph-positive CML in major molecular remission during therapy with imatinib.Leukemia · 2005
    Article
17. Cytogenetic abnormalities without evidence of relapse after treatment with imatinib and stem cell transplantation in a patient with Ph-positive ALL.International journal of hematology · 2005
    Article
18. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance.Leukemia · 2004
    Review
19. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia.Leukemia · 2004
    Article
20. Ph-positive and -negative myeloproliferative syndromes may co-exist.Leukemia · 2004
    Article

Corrections and comments

• Commented on by
  Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones.2003

Authors and funding

5 authors at 3 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as